CPL500036 · program
Alofropodect for Schizophrenia
Indications for CPL500036: Schizophrenia · Phase 2 Levodopa-induced dyskinesia in Parkinson's disease · Phase 2
Alofropodect (CPL'36), Celon Pharma's once-daily PDE10A inhibitor, for schizophrenia - the lead indication. In a Phase 2 trial of 189 patients with acute schizophrenia, CPL'36 20 mg and 40 mg once daily for 4 weeks significantly improved the PANSS positive subscale (primary endpoint) versus placebo by 3.7 points (Cohen's d 0.73) and 6.3 points (d 1.38), and the PANSS total score by 9.7 and 16.4 points (both p<0.001), with early signs of cognitive benefit at 40 mg. After a Type B meeting the FDA said the existing preclinical data are sufficient to start pivotal studies and agreed 'treatment of schizophrenia' is the appropriate indication; the planned Phase 3 program is two 28-day randomized, double-blind trials in acute schizophrenia plus a 12-month open-label extension, with drug-drug interaction, QTc and mass-balance studies run alongside. Celon expects to start the pivotal studies in 2026 and is seeking a global partner.
Development timeline
- metPeer-reviewed Phase 2 results published in CNS Drugs: both doses met the PANSS positive primary endpoint (-3.70 and -6.35 vs placebo); response rate (>=30% PANSS total reduction) 3.8% placebo, 15.4% 20 mg, 42.3% 40 mg.↗
- Celon announced positive FDA feedback from a Type B meeting: existing preclinical data are sufficient to start pivotal studies; the FDA endorsed a Phase 3 program of two 28-day acute trials plus a 12-month open-label extension. Celon expects to start pivotal studies in 2026. Program kept at phase_2 until a Phase 3 trial starts.↗
- FDA regulatory meeting / outcomeFDA Type B meeting clears the path to Phase 3 for CPL'36 in schizophrenia↗
- metPhase 2 in acute schizophrenia (n=189) met its primary endpoint: CPL'36 improved PANSS positive by 3.7 (20 mg) and 6.3 (40 mg) points vs placebo, and PANSS total by 9.7 and 16.4 points (all p<0.001).↗
- NCT05278156 completed (primary completion 2024-06-05, study completion 2024-06-19), 189 participants enrolled.
- Trial (portion) completedPhase 2 schizophrenia study of CPL500036 (NCT05278156) completed
- Phase 2 randomised, double-blind, placebo-controlled study NCT05278156 in acute schizophrenia started (189 patients; CPL500036 20 mg or 40 mg once daily vs placebo for 28 days; primary endpoint change in PANSS positive subscale at Day 28).
- First-in-human single and multiple ascending dose study in healthy volunteers (NCT03873324, 56 participants, Poland) completed; started 2018-12-20.
Readouts
- 2026-07-31ReportedFull resultsmetNCT05278156
Peer-reviewed Phase 2 results published in CNS Drugs: both doses met the PANSS positive primary endpoint (-3.70 and -6.35 vs placebo); response rate (>=30% PANSS total reduction) 3.8% placebo, 15.4% 20 mg, 42.3% 40 mg. ↗
- 2024-07-05ReportedTopline datametNCT05278156
Phase 2 in acute schizophrenia (n=189) met its primary endpoint: CPL'36 improved PANSS positive by 3.7 (20 mg) and 6.3 (40 mg) points vs placebo, and PANSS total by 9.7 and 16.4 points (all p<0.001). ↗
Clinical trials in Schizophrenia
NCT0527815602PDE2019Phase 2Completedn=189
Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia
NCT0387332401PDE2018Phase 1Completedn=56
Safety and Pharmacokinetics Study of CPL500036 Compound in Healthy Volunteers
Formulations
| Formulation | Route | Regimen | Pharmacokinetics |
|---|---|---|---|
| Alofropodect oral capsule (20 mg / 40 mg once daily) 20 mg or 40 mg PO once daily in the morning for 28 days in both Phase 2 trials (schizophrenia NCT05278156; levodopa-induced dyskinesia NCT05297201). Phase 1 (NCT03873324): single ascending doses in 7 cohorts and 14-day multiple ascending doses in 4 cohorts, with placebo capsules; the CNS Drugs paper reports safety and dose-dependent exposure up to 100 mg daily in Phase 1. | Oral | Once daily | — |
Mechanism of action
Potent, selective inhibitor of phosphodiesterase 10A (PDE10A), a dual cAMP/cGMP phosphodiesterase expressed almost exclusively in striatal medium spiny neurons. Inhibiting PDE10A raises cyclic-nucleotide signalling in both the D1 (direct) and D2 (indirect) pathway neurons; Celon describes alofropodect as a second-generation, fast-dissociating ('fast-off') inhibitor with preferential modulation of D2- over D1-mediated striatal pathways, which it proposes as the reason it succeeded where earlier PDE10A inhibitors (e.g. TAK-063/balipodect, MK-8189/elpipodect) did not. In vitro it inhibited PDE10A with an IC50 of 1 nM and, in a 44-target radioligand panel, interacted only with the muscarinic M2 receptor (negative allosteric modulator, IC50 9.2 uM). It inhibited the hERG tail current at IC25 3.2 uM without cardiovascular effects in 3D cardiac spheroids or dog telemetry, elicited catalepsy in rats at 0.6 mg/kg, and did not cause hyperprolactinaemia or hyperglycaemia at doses up to 3 mg/kg.
| Target | Action | Affinity |
|---|---|---|
| PDE10AprimaryPDE10A | Inhibitor | IC50 1 nMⓘ |
← Full CPL500036 compound page (identity, identifiers, all indications)
Sources
- Celon Pharma publikuje dane dla II fazy klinicznej czasteczki CPL'36 we wskazaniu schizofrenia (2024-07-05) — Strefa Inwestorow
- FDA Clears Celon Pharma's Schizophrenia Drug for Phase 3 Trial (2025-10-08) — Celon Pharma S.A. (via GlobeNewswire / BioSpace)
- Matloka M, et al. A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects. Front Pharmacol. 2022;13:999685 — Frontiers in Pharmacology / PubMed
- NCT03873324 (01PDE2018) - Safety and Pharmacokinetics Study of CPL500036 Compound in Healthy Volunteers — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT05278156 (02PDE2019) - Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia — ClinicalTrials.gov (U.S. National Library of Medicine)
- Wieczorek M, et al. CNS Drugs 2026 - full text (PK, adverse events, funding) — CNS Drugs (Springer) via PubMed Central
- Wieczorek M, et al. PDE10A Inhibition in Schizophrenia: A Randomised, Placebo-Controlled Phase 2 Study of Alofropodect (CPL'36) in Patients Experiencing Acute Schizophrenia. CNS Drugs. 2026;40(9):1295-1305 — CNS Drugs (Springer) / PubMed